Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis

Andersson, Anneli; Kelly, Matt; Imajo, Kento; Nakajima, Atsushi; Fallowfield, Jonathan; Hirschfield, Gideon; Pavlides, Michael; Sanyal, Arun J.; Noureddin, Mazen; Banerjee, Rajarshi; Dennis, Andrea; Harrison, Stephen A.

doi:10.1016/j.cgh.2021.09.041

Cited by 75 publications

(73 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This should be combined with genetic risk scores 19 . Moreover, it is of fundamental importance to identify non‐invasive biomarkers which are capable of detecting progression from simple steatosis to NASH, which is associated with an increased risk of hepatic and extra‐hepatic clinical events 20,21 . Similarly, it is important to integrate well defined hepato‐histological variables, such as zonation in NASH, 22 into a more comprehensive view of risk stratification of NAFLD/NASH/MAFLD in the individual patient.…”

Section: Research Agendamentioning

confidence: 99%

Precision medicine in nonalcoholic fatty liver disease

Lonardo

2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Section: Research Agendamentioning

confidence: 99%

Precision medicine in nonalcoholic fatty liver disease

Lonardo

2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

“…In lieu of liver biopsy, MRI with protondensity fat fraction and elastography, has been utilized in early, phase 1 and 2a trials for screening and therapeutic response as a primary endpoint in patients with NAFLD. [38] Several active prospective consortia are investigating the progression of NAFLD to HCC beyond known traditional risk factors. The maturation of large collaborative efforts from the NASH CRN, National Cancer Institute's U01 Translational Liver Cancer (TLC) consortium, the Hepatocellular carcinoma Early Detection Strategy (HEDS) cohort, and the Texas Hepatocellular Carcinoma Consortium (THCCC) cohort can help answer key knowledge gaps in our understanding of the biomarkers and risk factors associated with NAFLD-related HCC.…”

Section: Opportunities Aheadmentioning

confidence: 99%

Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease

Cholankeril

El–Serag

2022

Semin Liver Dis

View full text Add to dashboard Cite

The burden for hepatocellular carcinoma (HCC) attributed to nonalcoholic fatty liver disease (NAFLD) continues to grow in parallel with rising global trends in obesity. The risk of HCC is elevated among patients with NAFLD-related cirrhosis to a level that justify surveillance based on cost-effectiveness argument. The quality of current evidence for HCC surveillance in all patients with chronic liver disease is poor, and even lower in those with NAFLD. For a lack of more precise risk-stratification tools, current approaches to defining a target population in non-cirrhotic NAFLD are limited to noninvasive tests for liver fibrosis, as a proxy for liver-related morbidity and mortality. Beyond etiology and severity of liver disease, traditional and metabolic risk factors, such as diabetes mellitus, older age, male gender and tobacco smoking, are not enough for HCC risk stratification for surveillance efficacy and effectiveness in NAFLD. There is an association between molecular and genetic factors and HCC risk in NAFLD, and risk models integrating both clinical and genetic factors will be key to personalizing HCC risk. Herein in this review, we discuss concerns regarding defining a target population, surveillance test accuracy, surveillance underuse, and other cost-effective considerations for HCC surveillance in individuals with NAFLD.

show abstract

“…Finally, after performing the aforementioned manual quality control on the S2S values, all values were between -48.3 to 70. 5…”

Section: Image Registration and Mesh Constructionmentioning

confidence: 99%

“…Significant progress has been made in recent years in the use of non-invasive imaging methods to measure the pathological changes that are features of increasingly common liver conditions. This includes non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) including steatosis or fat accumulation [2,3], fibro-inflammation [4,5] and fibrosis [6]. The prevalence of these conditions, associated with obesity, insulin resistance and type-2 diabetes (T2D), are likely only to increase further given the current obesogenic environment.…”

Section: Introductionmentioning

confidence: 99%

Liver Shape Analysis using Statistical Parametric Maps at Population Scale

Thanaj¹,

Basty²,

Cule³

et al. 2022

Preprint

View full text Add to dashboard Cite

Morphometric image analysis enables the quantification of differences in the shape and size of organs between individuals. Here we have applied morphometric methods to the study of the liver by constructing surface meshes from liver segmentations from abdominal MRI images in 33,434 participants in the UK Biobank. Based on these three dimensional mesh vertices, we evaluated local shape variations and modelled their association with anthropometric, phenotypic and disease traits, including liver disease and type-2 diabetes. We found that age, body mass index, hepatic fat and iron content, as well as, health traits were significantly associated with regional liver shape and size. Interaction models in disease groups showed that the presence of type-2 diabetes accelerates age-related changes in the liver, while presence of liver fat further increased shape variation in both type-2 diabetes and liver disease. The results suggest that this novel approach may greatly benefit studies aiming at better categorisation of pathologies associated with acute and chronic liver conditions.

show abstract

Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis

Cited by 75 publications

References 58 publications

Precision medicine in nonalcoholic fatty liver disease

Precision medicine in nonalcoholic fatty liver disease

Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease

Liver Shape Analysis using Statistical Parametric Maps at Population Scale

Contact Info

Product

Resources

About